Drug intelligence / Profile preview

ID11916

Development stage: Preclinical
Lead developer: Idience
Modality: Small Molecules
Administration: Oral

Overview

ID11916 is a small molecule dual inhibitor that acts as both an androgen receptor antagonist and a phosphodiesterase 5 inhibitor. It is being developed by Idience and Ildong Pharmaceutical for the treatment of various solid tumors, including breast cancer, gastric cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), and triple-negative breast cancer (TNBC). The drug is currently in preclinical development stages, with ongoing research particularly focused in South Korea.

Targets

PARP (PARP family)

Beyond the preview

Go deeper on ID11916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ID11916.

Explore the full profile